← Leaderboards
Vicki Nienaber
Zenobia Therapeutics, Inc
$1,182,878
Attributed
$1,182,878
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $456.3K · FY2009–17$500K$375K$250K$125K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$1,182,878 · 3
By mechanism
R43$1,182,878 · 3
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Libraries”
- David Heimbrook · Leidos Biomedical Research, Inc.$860,725,506
- Leonard Freedman · Leidos Biomedical Research, Inc.$792,858,643
- Richard A Gibbs · Baylor College Of Medicine$428,954,539
- Lynn Briscoe · Leidos Biomedical Research, Inc.$225,263,761
- Leonard Freedmand · Leidos Biomedical Research, Inc.$160,413,316
- Robert H Waterston · Washington University$155,287,704
Research focus
LibrariesDrug DiscoveryCrystallizationLeadPharmaceutical PreparationsInhibitor/AntagonistLigandsProteinsLiteratureBaseSiteStructureProgramsPublic Health RelevanceEnzymesTherapeutic AgentsPharmaceutical ChemistryMedicalInterestHigh Throughput ScreeningAssay DevelopmentFeedingEnzyme ActivatorsBiochemical
Grant awards (4)
I-Corp Program fro HOT-ROXS: An integrated platform for identifying activators of "non-druggable" targets$50,000
R43 · FY2017 · TR · contact PI
HOT-ROXS: An integrated platform for identifying activators of "non-druggable" targets using biophysical screening, x-ray solution scattering and high-throughput co-crystallization$347,750
R43 · FY2016 · TR · contact PI
Discovery of inhibitors of the lipopolysaccharide synthesis pathway enzymes LpxA$456,299
R43 · FY2010 · AI · contact PI
Discovery of inhibitors of ALK for the treatment of cancer$328,829
R43 · FY2009 · CA · contact PI